Infinity Pharmaceuticals, Inc.

Sanofi-A Ventis Deutschland Gmbh

Millennium Pharmaceuticals Limited

Harvard College

Aventis Pharma Deutschland, Gmbh

Erasmus University Medical Center

Surface Oncology, Inc.

Vito J Palombella

Alfredo C Castro

David Guenther Winkler

Julian Adams

Louis Grenier

Francois Soucy

Olaf Ritzeler

Jeffery L Kutok

Wayne William Hancock

Martin R Tremblay

Catherine Anne Evans

Tao Liu

Andre Lescarbeau

Somarajannair Janardanannair

Hormoz Mazdiyasni

Ross L Stein

Frank Grosveld

Pamela M Holland

Alfred L Goldberg

Stephen J Brand

Jonathan Hill

Thomas P Maniatis

Alison Paterson

Sha-Mei Liao

Peter J Elliott

Eric S Lightcap

Oliver Rando

Hormoz Mazdiyashi

Lawrence R Dick

Gopalakrishna R Vaddi

Dan R Burns

Teresa A McCormack

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Heterocyclic compounds and uses thereof

Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.

Anti-CD47 antibodies and methods of use

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).

Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors

The subject matter of the present invention is directed to novel substituted &#x3b2;-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I&#x3ba;B kinase is involved.

Substituted &#x3b2;-carbolines

The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I,which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I&#x3ba;B kinase is involved.

Substituted beta-carbolines

The invention provides full-length, human isolated nucleic acids molecules, designated MEKK1 nucleic acid molecules, which encode a MEKK family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MEKK1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MEKK1 gene has been introduced or disrupted. The invention still further provides isolated MEKK1 proteins, fusion proteins, antigenic peptides and anti-MEKK1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

MEKK1 molecules and uses thereof

Disclosed herein is a method for regulating the activity of NF-&kgr;B in an animal comprising contacting cells of the animal with certain proteasome inhibitors.

Proteasome regulation of NF-KB activity

Substituted beta carbolines

The invention relates to methods for measuring proteasome activity in biological samples. More particularly, then invention relates to methods for monitoring drug action following in vivo administration of a proteasome inhibitor. The invention provides methods and kits for monitoring pharmacodynamic drug action and for determining dose regimen for a proteasome inhibitor. The invention also provides methods for determining baseline proteasome activity in a mammal.

Method for monitoring proteasome inhibitor drug action

Growing community of inventors

Needham, MA, United States of America

Vito J Palombella